Andrew C. von Eschenbach
Andrew C. von Eschenbach, M.D., is an advisor and former chairman of the Manhattan Institute's Project FDA. From September of 2005 to January 2009 he served as commissioner of the U.S. Food and Drug Administration where he championed an agenda to modernize the FDA. Dr. von Eschenbach joined FDA after serving for four years as director of the National Cancer Institute (NCI) at the National Institutes of Health where he set an ambitious goal to eliminate the suffering and death due to cancer by rapid acceleration and integration of the discovery-development-delivery continuum.
Tom Coburn, M.D.
Former Oklahoma Senator Tom Coburn, M.D. is an advisor to the Manhattan Institute's Project FDA. During his two terms in the US Senate (2005-2015), Dr. Coburn served on the committees on Banking, Housing, and Urban Affairs; Health, Education, Labor, and Pensions; and Intelligence. While in the Senate, he was also the ranking member of the Committee on Homeland Security. From 1995–2001, Dr. Coburn represented Oklahoma's 2nd Congressional District in the U.S. House of Representatives. A family physician, Coburn was a Member of the Committee on Commerce where he sat on the subcommittees on Health & Environment as vice-chairman, Energy & Power, and Oversight and Investigations. Near the end of 2001, after the completion of his third congressional term, Coburn was selected co-chair of the President's Advisory Council on HIV/AIDS. A longtime advocate of FDA reform, Dr. Coburn introduced the "Promoting Accountability, Transparency, Innovation, Efficiency, and Timeliness at FDA" act with Senator Richard Burr in 2012. Dr. Coburn continued to see patients while he served in Congress.
John F. Crowley, JD, MBA
John F. Crowley is chairman and CEO of Amicus Therapeutics, Inc. His involvement with biotechnology stems from the 1998 diagnosis of two of his children with Pompe disease. In his drive to find a cure, Crowley left his position at Bristol-Myers Squibb and founded Novazyme Pharmaceuticals. He and his family have been profiled on the front page of The Wall Street Journal and are the subjects of a book by Pulitzer prize-winning journalist Geeta Anand, The Cure: How a Father Raised $100 Million-And Bucked the Medical Establishment-In a Quest to Save His Children. He serves on the executive committee of the national board of directors of the Make-A-Wish Foundation of America and is a founding board member of the Global Genes Project.
Arthur Daemmrich, Ph.D., is an associate professor at the University of Kansas School of Medicine in the Department of History and Philosophy of Medicine, with affiliations in the Department of Health Policy and Management and the Department of Preventive Medicine and Public Health. His research examines historical dimensions of medical and public health risk management, especially the history of pharmaceutical regulation, environmental health regulation, and chemical testing programs.
Joseph DiMasi, Ph.D., is Director of Economic Analysis at the Tufts Center for the Study of Drug Development at Tufts University. His research is focused on the new drug development and regulatory review processes and the economics of the pharmaceutical industry. Dr. DiMasi presents his work at numerous professional and industry conferences in the United States and abroad and has testified before the U.S. Congress in hearings leading up to the FDA Modernization Act of 1997 and reauthorization of the Prescription Drug User Fee Act.
Henry G. Grabowski
Henry G. Grabowski, Ph.D., is a faculty member in the Health Sector Management Program Faculty, a Professor of Economics and the Director of the Program in Pharmaceuticals and Health Economics at Duke University. Dr. Grabowski has published numerous studies on the pharmaceutical industry with his principal research involving the economics of the innovation process, business regulation, industrial organization, and developing therapies for Southern countries.
James J. Hsieh, M.D., Ph.D.
James J. Hsieh, M.D., Ph.D., is an associate member at the Human Oncology and Pathogenesis Program and an associate attending physician at the Genitourinary Oncology Division at the Memorial Sloan-Kettering Cancer Center, and an associate professor at the Weill-Cornell Medical College. He was a tenured faculty member at Washington University before joining the MSKCC in 2010. Dr. Hsieh obtained his M.D. in Taiwan, conducted his Ph.D. thesis at the Johns Hopkins University, and finished his Medical Oncology Fellowship at the Dana-Farber Cancer Institute at Harvard Medical School. His clinical practice and research focused on kidney cancer. He founded the Translational Kidney Cancer Research Program at the MSKCC in 2011.
Paul Howard, Ph.D., is a senior fellow and the director of the Manhattan Institute's Center for Medical Progress. He focuses his research on a wide variety of medical policy issues, including medical innovation, FDA reform, and consumer-driven health care.
Peter Huber is a senior fellow at the Manhattan Institute writing on the issues of drug development, energy, technology, and the law. Huber is the author of the forthcoming book, The Cure in the Code: How 20th Century Law Is Undermining 21st Century Medicine (Basic Books, 2013.) He wrote The Bottomless Well, coauthored with Mark Mills, which Bill Gates said "is the only book I've ever seen that really explains energy, its history and what it will be like going forward".
Daniel P. Petrylak
Daniel P. Petrylak, M.D., is an Associate Professor of Medicine and the Program Director of the Genitourinary Oncology Section in the Division of Hematology/Oncology at the Columbia University Medical Center. Dr. Petrylak has served on the program committee for the annual meetings of the American Urological Association (2003-7) as well as for the American Society of Clinical Oncology (1995-7, 2001-3). He also has served as a committee member for the Devices and Immunologicals section of the Food and Drug Administration Dr. Petrylak was instrumental in the clinical development of docetaxel for prostate cancer, and he chaired one of the trials that supported its approval for prostate cancer by the FDA in 2004. He was also one of the principal investigators on the SPARC trial, an international registration study of satraplatin, an oral chemotherapy agent, for patients who failed on chemotherapeutic regimen for prostate cancer
Tomas J. Philipson
Tomas J. Philipson, Ph.D., is a professor at the Harris School for Public Policy at the University of Chicago. He is an associate member of the Department of Economics and has been a Senior Lecturer at the Law School. Dr. Philipson's research focus is on health economics. He served in the Bush Administration as the Senior Economic Advisor to the head of the Food and Drug Administration (FDA) during 2003-04, as the Senior Economic Advisor to the head of the Centers for Medicare and Medicaid Services (CMS) in 2004-05 and is currently serving on an eight member health care task force for Senator John McCain's campaign for President of the United States.
Lance K. Stell
Lance K. Stell, Ph.D., FACFE, is the John and Mary West Thatcher Professor of Philosophy, Davidson College, Davidson, NC, where he serves as Director of the Medical Humanities Program. He also holds appointments as Clinical Professor in the Department of Internal Medicine, at Carolinas Medical Center, Charlotte, NC, and as Full Professor (Adjunct), in the Translational Science Institute, at Wake Forest University School of Medicine, Winston-Salem, NC. Dr. Stell is a Fellow and Diplomate in the American College of Forensic Examiners. He consults and serves as an expert witness in criminal and civil cases in which the ethical standards of health care professionals are implicated. He publishes in ethics, medical ethics and philosophy of law. In 2005, the NC Medical Society recognized Dr. Stell's service to the medical profession with the John Huske Anderson award, the highest honor the Medical Society bestows on a non-physician.
E. Fuller Torrey
E. Fuller Torrey MD is the Executive Director of the Stanley Medical Research Institute (SMRI) in Chevy Chase, Md. and the founder of the Treatment Advocacy Center in Arlington, VA. SMRI funds approximately 50 treatment trials at any given time for schizophrenia and bipolar disorder. Dr. Torrey was educated at Princeton, McGill and Stanford Universities and is the author of 20 books.